Breadcrumb

Fatima Karzai, M.D.

Fatima Karzai, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Genitourinary Malignancies Branch

RESEARCH SUMMARY

Dr. Karzai is an internationally recognized physician with expertise in all stages of prostate cancer and clinical trial development.  Her clinical research program includes genetics/genomics, imaging, immunotherapy, and health disparities. Dr. Karzai is passionate about patient care and improving the lives of patients with cancer. Dr. Karzai’s mission is to deliver exemplary clinical care to patients involved in innovative clinical trials, while pursuing her goals of combining scientific advancement and leadership. Dr. Karzai also provides mentorship to women in medicine.

In addition, Dr. Karzai is the NCI Deputy Clinical Director.

Areas of Expertise

Immuno-Oncology
Prostate Cancer
Targeted Therapies
Genetics And Genomics
Women In Medicine
Health Disparities
Leadership

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Clinical Trials

Publications

Selected Key Publications

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer

Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL.
BJU Int. 116(4): 546-555, 2015. [ Journal Article ]

Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, Madan RA, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL.
Clin Genitourin Cancer. 15(1): 77-85, 2017. [ Journal Article ]

Metabolic syndrome in prostate cancer: impact on risk and outcomes

Karzai FH, Madan RA, Dahut WL.
Future Oncol. 12(16): 1947-1955, 2016. [ Journal Article ]